Distribution of CD4+CD25+ T cells and graft-versus-host disease in human hematopoietic stem cell transplantation |
Dae Hyoung Lee1, Nak Gyun Chung2, Dae Chul Jeong2, Bin Cho2, Hack Ki Kim2 |
1Department of Pediatrics, College of Medicine, Hallym University, Seoul, Korea 2Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea |
사람의 동종 조혈모세포이식에서 CD4+CD25+ T세포의 분포와 이식편대숙주병 |
이대형1, 정낙균2, 정대철2, 조 빈2, 김학기2 |
1한림대학교 의과대학 소아과학교실 2가톨릭대학교 의과대학 소아과학교실 |
Correspondence:
Bin Cho, Email: chobinkr@catholic.ac.kr |
|
|
Abstract |
Purpose : This study aimed to determine the frequencies of CD4+CD25+ T cells in donor graft and peripheral blood CD4+CD25+ T cells in recipients after hematopoietic stem cell transplantation (HSCT) and their association with graft-versus-host disease (GVHD).
Methods : Seventeen children who underwent HSCT were investigated. CD4+CD25+ T cells in samples from donor grafts and recipient peripheral blood were assessed by flow cytometry at 1 and 3 months after transplantation.
Results : CD4+CD25+ T cell frequencies in the grafts showed no significant difference between patients with and without acute GVHD (0.90% vs. 1.06%, P=0.62). Absolute CD4+CD25+ T cell number in grafts were lower in patients with acute GVHD than in those without acute GVHD (6.18×105/kg vs. 25.85×105/kg, P=0.09). Patients without acute GVHD showed a significant decrease in peripheral blood CD4+CD25+ T cell percentage at 3 months compared to those at 1 month after HSCT (2.11% vs. 1.43%, P=0.028). However, in patients with acute GVHD, CD4+CD25+ T cell percentage at 3 months was not different from the corresponding percentage at 1 month after HSCT (2.47% vs. 2.30%, P=0.5).
Conclusion : The effect of frequencies of CD4+CD25+ T cells in donor grafts on acute GVHD after HSCT could not be identified, and the majority of peripheral blood CD4+CD25+ T cells in patients who underwent HSCT may be activated T cells related to acute GVHD rather than regulatory T cells. Further studies with additional markers for regulatory T cells are needed to validate our results. |
Key Words:
Regulatory T cell, Graft-versus-fost Disease, Allogeneic hematopoietic stem cell transplantation |
|